MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer

被引：1
|
作者：
Goetz, Matthew
Toi, Masakazu
Huober, Jens
Sohn, Joo Hyuk
Tredan, Olivier
Park, Inhae
Campone, Mario
Chen, Shin-Cheh
Manso, Luis Manual
Paluch-Shimon, Shani
Freedman, Orit C.
Andre, Valerie
Saha, Abhijoy
van Hal, Gertjan
Shahir, Ashwin
Iwata, Hiroji
Johnston, Stephen R. D.
O'Shaughnessy, Joyce
Pivot, Xavier
Tolaney, Sara
Hurvitz, Sara
Llombart, Antonio
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-GS01-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS01-12
引用
收藏
页数：3
相关论文
共 50 条
  • [1] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. C.
    Sanchez, L. M. Manso
    Paluch-Shimon, S.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1384
  • [2] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
    Sledge, G. W.
    Toi, M.
    Neven, P.
    Sohn, J.
    Inoue, K.
    Pivot, X.
    Burdaeva, O.
    Okera, M.
    Masuda, N.
    Kaufman, P. A.
    Koh, H.
    Grischke, E-M.
    Conte, P. F.
    Lu, Y.
    Barriga, S.
    Hurt, K.
    Frenzel, M.
    Johnston, S. R. D.
    Llombart-Cussac, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
  • [3] Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: final overall survival results of MONARCH 3
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. -C.
    Manso, L. M.
    Paluch-Shimon, S.
    Freedman, O. C.
    O'Shaughnessy, J.
    Pivot, X.
    Tolaney, S. M.
    Hurvitz, S. A.
    Llombart-Cussac, A.
    Andre, V.
    Saha, A.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 718 - 727
  • [4] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
    Grischke, Eva Maria
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Masuda, Norikazu
    Kaufman, Peter
    Koh, Han
    Conte, Pierfranco
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
  • [5] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
  • [7] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
  • [8] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [9] Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2-advanced breast cancer
    Goetz, M. P.
    Johnston, S.
    Martin, M.
    Tokunaga, E.
    Park, I. H.
    Huober, J.
    Toi, M.
    Price, G. L.
    Boye, M.
    Li, L.
    Forrester, T.
    Gainford, C.
    Gable, J.
    Carter, G. C.
    Sood, A.
    Dileo, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2-advanced breast cancer
    Hong, Juan
    Chen, Tujia
    Ouyang, Lihui
    Du, Ning
    Li, Anna
    Zhou, Zhongqi
    Zhang, HaiLing
    Xia, Zhengzheng
    Meng, Jun
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (04) : 559 - 566
12345